The global pen needles market size was USD 1.23 Billion in 2022 and is expected to register a revenue CAGR of 11.5% during the forecast period.
- The 4 mm segment is expected to register a rapid revenue growth during the forecast period.
- The insulin therapy segment is expected to register a rapid revenue growth rate during the forecast period.
- The allergic reactions segment is expected to grow at a steady CAGR during the forecast period.
- The Asia Pacific pen needles market is expected to register a rapid revenue growth rate during the forecast period
- The North America pen needles market is expected to account for largest revenue share during the forecast period.
- The Europe market is expected to register a steady CAGR during the forecast period.
Request a Sample@ https://www.qyresearchmedical.com/sample/119582
Report Scope of the Pen Needles Market:
|The market size value in 2022||USD 1.23 Billion|
|CAGR (2023 – 2032)||11.5%|
|The Revenue forecast in 2032||USD 3.12 Billion|
|Quantitative units||Revenue in USD Billion
CAGR from 2023 to 2032
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
Increasing prevalence of various chronic diseases such as cancer and diabetes, increasing number of patients suffering from allergic reactions or requiring hormone replacement therapies, growing adoption of injectable devices and products for drug administration as well as rising advancement and improvement in insulin pen needles are key factors driving market revenue growth.
Cancer and chronic diseases, such as osteoporosis, Cardiovascular Diseases (CVD) and multiple sclerosis, are among the top causes of death and disabilities worldwide, hence disease incidence from these conditions is not only increasing but also spreading across every location and socioeconomic background. According to WHO, incidences of chronic diseases, such as diabetes and Cardiovascular Diseases (CVD) and Chronic Respiratory Diseases (CRD), will account for almost three-quarters of deaths occurring worldwide and equivalent to 71% of all deaths globally. Every year, over 15 million deaths, ofpeople aged between 30 and 69, are caused by chronic diseases and 85% of these untimely deaths occur in low and middle-income countries. These countries account for 77% of all Non-Communicable Diseases (NCD) mortality.
Many new injectable medications, whether original composition or generic, have entered the market in previous decade for treating a rising number of patients suffering from chronic diseases, malignancies, or autoimmune diseases. There is currently a multitude of diverse streams of innovation plans for future injectable products for drug administration, which has resulted in a rising demand for injectable pen needles. Rising advancement and improvement in insulin pen needles is one of the major factors driving market revenue growth. For instance, pen needles developed by Becton, Dickinson, and Company (BD) use cutting-edge technology, inventive design, and cutting-edge manufacturing techniques. In a 4-mm size, their pen needle design optimizes injection comfort by utilizing Penta PointTM Comfort technology, Microbonded lubrication (applied during needle manufacture to help the needle smoothly slide into the skin), and Electropolishing. On 22 September 2020, HTL-STREFA released Droplet Micron, a new and revolutionary pen needle designed to provide best injection experience. Droplet Micron is finer and smaller than other pen needles in the market, measuring 34 gauges and 3.5mm. Droplet Micron decreases penetration load applied for injection by up to 50%; an earlier study has connected penetration force reduction to a less uncomfortable injection experience. Despite smaller needle length, Droplet Micron provides same dependability, safety, and efficacy as regular pen needles. Another Droplet Micron innovation is its tapering and polished needle tip, which is designed for optimal comfort, hence, was preferred by 98% of customers. These advancements in pen needle technology are enhancing clinical results and improving patient care and experience, thus driving market revenue growth.
According to the International Diabetes Foundation, roughly 537 million persons (20-79 years) suffered from diabetes in 2021 and total number of diabetes patients is expected to climb up to 643 million by 2030 and 783 million by 2045. Most effective treatments are injectable such as insulin and glucagon-like peptide-1s (GLP-1s). Disposable and sterile pen needles with clear labelling for precise insulin administration have replaced early glass and metal syringes that are required for boiling sterilizing. Early needles, which range in length from 19 to 26 mm and required hand sharpening on a whetstone, have given a way to pen needles of 6 mm and 4 mm in length as thin as 34 gauge. These advancements, together with advancements in pen needle shell and tip structure, have resulted in a better injection experience for diabetics.
One of the greatest life-changing advancements in diabetic care has been insulin pen needle. These insulin injection needles are utilized by over 95% of millions of diabetics globally and provide greater convenience and minimal pain than insulin syringe equivalents. These needles, which can be as thin and narrow as a few human hairs, are frequently intended to cause minimal pain and enhance insulin delivery into the body. Insulin pen needles vary in length from 4 mm to 12 mm and in diameter from 29 to 32 gauge. Insulin pens are increasingly small, thin, and often painless owing to technological improvements in pen needles. For instance, BD (Becton, Dickinson, and Company) introduced the world’s smallest pen needle, BD Ultra-FineTM Nano. This needle is equally effective as long needles for patients of diverse body ranges and provide a less unpleasant injection experience for over 5 million of Americans, who inject insulin or GLP-1 to treat their diabetes. These factors are expected to drive market revenue growth.
Competitive landscape of the global pen needles market is fragmented with many key players operating at global and regional levels. These players are engaged in product development and strategic alliances to expand their respective product portfolio and gain a robust footing in the global market. Major players operating in the market include Becton, Dickinson and Company, Novo Nordisk A/S, Ypsomed Holding AG, UltiMed, Hindustan Syringes and Medical Devices, PromiseMed Diabetes Care, HTL-STREFA, ARKRAY, Links Medical Products, and GlucoRx. Market players are undertaking various strategies, which is expected to drive market revenue growth during the forecast period.
Pen Needles Market Segmentations:
|By Needle Length||By Product Type||By Application||Regional scope|
Glucagon-like Peptide-1 (glp-1) therapy
Hormone Replacement Therapy
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1599 https://www.qyresearchmedical.com/report/checkout/119582/
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: